1、American Conference of Governmental Industrial Hygienists TLVs and BEIs. Threshold Limit Values for Chemical Substances and Physical Agents and Biological Exposure Indices. Cincinnati, OH, 2008, 2、內(nèi)容：Totsuka K，F(xiàn)urukawa M，F(xiàn)uruya N，et al. PK/PD analysis of Tebipenem Pivoxil (ME1211),a Novel Oral Carbapenem Antibiotic,in otolaryngological infections,a phase II clinical trial （3）.45th Intersci Conf Antimicrob Agents Chemother（ICAAC）（Dec 16-19. Washington，D.C.），2005，Abst L-579標(biāo)題 PK/PD analysis of Tebipenem Pivoxil (ME1211),a Novel Oral Carbapenem Antibiotic,in otolaryngological infections,a phase II clinical trial； 3、PK–PD analysis of tebipenem pivoxil in clinical trials for pediatric patients. Jpn J Chemother. 2009;57(S-1):186–91. 4、Effect of meals and dosage-form modification on theophylline bioavailability from a 24-hour sustained-release delivery system. González MA1, Straughan AB. 5、Single dose study of the bioequivalence of two sustained-release theophylline formulations. Contreras J, Pérez N, González R, Ontivero E, López M. Arzneimittelforschung. 1998 Mar;48(3):259-62. 6、National Technical Information Service. (Springfield, VA 22161) Formerly U.S. Clearinghouse for Scientific & Technical Information., AD277-689 7、Graul, A.; Castaner, J.; Atorvastatin Calcium. Drugs Fut 1997, 22, 9, 956. 8、Formulation And Evaluation of Topical Aceclofenac Gel Using Different Gelling Agent（JAPAN PATEL1*, BRIJESH PATEL1, HARDEEPSINGH BANWAIT1, KAUSHAL PARMAR1,MANISH PATEL2 Department of Pharmaceutics, Sat Kaival College of Pharmacy, Sarsa, Anand, Gujarat, India Nootan Pharmacy College, Visnagar, Gujarat, India） 9、NCCN pediatric neuroblastoma practice guidelines. The National Comprehensive Cancer Network. Oncology (Williston Park). 1996 Dec;10(12):1813-22 10、Preliminary studies on toxic effects of some vulcanizing accelerators 11、Dose Dumping Dose dumping is an increased concern with drugs manufactured as modified-release (MR) formulations, that is, where drug   [更多]

1、Effect of probenecid or diet on tebipenem pivoxil tablets pharmacokinetics in healthy male volunteers； 2、Effect of diet on the pharmacokinetics of tebipenem pivoxil fine granules in healthy male volunteers； 3、Pharmacokinetics analysis of tebipenem pivoxil in a phase II clinical trial in otolaryngological infection 1、Pharmacokinetic properties of isosorbide-5-mononitrate under fasting and fed conditions in healthy male subjects. Jin C, Jeon JY, Im YJ, Jeong JA, Kim Y, Chae SW, Bentz J, Kumke T, Kim MG. 7.The control of myopia with atropine.   [更多]

1.Myopia Control with Bifocal Contact Lenses:?A Randomized Clinical Trial 2.The Role of Atropine Eye Drops in Myopia Control 4. Myopia Control: A Review 7. Efficacy of 1%?atropine?eye drops in retarding progressive axial myopia in Indian eyes 8.Atropine?0.01% Eyedrops Significantly Reduce the Progression of Childhood Myopia 9.Current approaches to myopia control 10.Atropine?for the Prevention of Progression in Myopia - Data, Side Effects, Practical Guidelines 13. Atropine?0.01% Eyedrops Significantly Reduce the Progression of Childhood Myopia. 18. The treatment of myopia with?atropine?and bifocals. A long-term prospective study 19. Inhibitory effects of apomorphine and?atropine?and their combination on myopia in chicks 20. The penetration and distribution of topical?atropine?in animal ocular tissues. 21. Treatment outcomes of?myopic?anisometropia with 1%?atropine: a pilot study 23. Does?atropine?use increase intraocular pressure in?myopic?children? 24. Atropine?use for the prevention of myopia progression 25. Allergic reactions to?atropine?eye drops for retardation of progressive myopia in children. 29. Maximum?atropine?dose without clinical signs or symptoms. 31. Atropine?and bifocals can slow the progression of myopia in children. 33. Prevention of myopia onset with 0.025%?atropine?in premyopic children 35. The long-term results of using low-concentration?atropine?eye drops for controlling myopia progression in schoolchildren. 37. Prevention of myopia progression with 0.05%?atropine?solution.   [更多]

1、P. A. Prajapati and M. M. Patel, “Formulation and in vitro evaluation of atropine sulphate viscous ocular solutions for the mydriatic and cycloplegic effect,”?International Journal of Pharmaceutical and Applied Sciences, vol. 1, no. 2, pp. 70–78, 2010.?View at Google Scholar 2、D. S. Satya, K. P. Suria, and P. P. Muthu, “Advanced approaches and evaluation of ocular drug delivery system,”?American Journal of PharmTech Research, vol. 1, no. 4, pp. 72–92, 2011.?View at Google Scholar 3、B. K. Nanjwade, D. B. Sonaje, and F. V. Manvi, “In vitro—in vivo?release of ciprofloxacin from ophthalmic formulations,”?International Journal of Pharmacy and Biotechnology, vol. 1, no. 1, pp. 23–28, 2011.?View at Google Scholar 4、Physicochemical properties and stability of nicorandil By Nagai, Hiroshi; Koizumi, Ikue; Haneda, Masatoshi; Imai, Toshikatsu; Kikuchi, Mineo; Shiba, Motoharu From Iyakuhin Kenkyu (1983), 14(6), 968-79. Language: Japanese, Database: CAPLUS 5、Sobean oil partially hydrogenated 最新德國藥典   [更多]

1.Arzneimittel Forschung/Drug research 1986 36(2)，p291-303. 2.The use of antithrombotic drugs in artery disease 3. Jonassen IB, Havelund S, Ribel U, et al. Insulin Degludec is a new generation ultra-long acting basal insulin with a unique mechanism of protraction based on multi-hexamer ormation [J]. Diabetes, 2010, 59(Suppll): All(39-OR). 4.Korsatko S, Deller S, Zahiragic S, et al. Ultra-long-acting insulin degludec: two different formulations (U100 and U200) are bioequivalent and show similar pharmacodynamics [abstract no. 2349-PO]. Diabetes. 2011;60 Suppl:A624. 5.Technology Reports of the Osaka University, , vol. 7, p. 177,182。   [更多]

1、Drugs Fut 1989, 14(9): 875 ISSN 0377-8282 Copyright Clarivate Analytics CCC: 0377-8282 DOI: 10.1358/dof.1989.014.09.103408 2、Dionne, G. (BioChem Pharma Inc.); 1,3-Oxathiolane nucleoside analogues. EP 0526253; JP 1995500317; US 5538975; WO 9303027 . 3、Hoshi, A.; Casta?er, J.; Capecitabine. Drugs Fut 1996, 21, 4, 358 4、Indian Journal of Chemistry, Section B: Organic Chemistry Including Medicinal Chemistry, 1997, vol. 36, # 9, p. 816 - 818 5、DETERMINATION OF CLENBUTEROL HYDROCHLORIDE BY SEQUENTIAL INJECTION ANALYSIS COUPLED WITH CHEMILUMINESCENCE DETECTION 6、[Bioanalytic examination and pharmacokinetics of captopril. Bioequivalence studies of different captopril-containing Tensiomin preparations]. 7、Agrati A. M., De Bartolo G., Palmieri G., Minerva Med., 83, 533-536(1992) 8、Dawes J., Hodson B. A., Pepper D. S., Thromb. Haemost, 62, 945-949(1989) 9、with mercury(II) diacetate,trifluoroacetic acid . Acta Chimica Hungarica 1986 vol.122 3-4 p261-272   [更多]

藥物研發(fā)中心全套質(zhì)量管理體系文件，越詳細(xì)越好，價格可談！   [更多]

1.論批生產(chǎn)記錄設(shè)計的有效性對產(chǎn)品質(zhì)量追溯的影響——以公司內(nèi)膠囊及片劑產(chǎn)品批生產(chǎn)記錄為例 2.Federal Health bulletin 4（1961）12:189 需要這個文獻(xiàn) 3.Morton RF, et al. Studies on the absorption, diffusion, and excretion of cycloserine. Antibiot Annu 1955-56; 3: 169-72. 4.Acta Gastroenterol Belg.1969,32（10）：771-777 A NEW ANTISPASMODIC DRUG IN THE TREATMENT OF BILIARY AND INTESTINAL DISCASCS:A CLINICAL TEST. 5.a process for preparing (S)-1-(3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one https://priorart.ip.com/IPCOM/000238343   [更多]

簡介：藥智人才是最專業(yè)的醫(yī)藥產(chǎn)業(yè)招聘平臺，與許多醫(yī)藥行業(yè)的知名企業(yè)都有合作，職位種類豐富，崗位更專業(yè)~ 賺取賞金規(guī)則（活動時間：5月13日-5月17日）： 1.免費(fèi)注冊/登錄藥智人才（https://job.yaozh.com/），上傳簡歷： 簡歷完善度≥80 可獲得50元賞金； 2.簡歷完成后，并截圖藥智人才簡歷板塊的完善度提交審核，并且備注藥智人才的用戶名/注冊手機(jī)信息； 3.審核通過后，賞金會在3個工作日內(nèi)審核并發(fā)放，如提交后有刪除簡歷的行為，視為作弊處理，對應(yīng)賞金將會被凍結(jié)不予提現(xiàn)。 4.特別福利：簡歷完善后既有機(jī)會直接內(nèi)推給名企噢~ 溫馨提示： 1.如果疑問可以聯(lián)系客服QQ：3413833812 2.一經(jīng)發(fā)現(xiàn)求職者在上傳簡歷期間有作弊等行為，藥智人才將取消其賞金并凍結(jié)該筆提現(xiàn)。 3.在法律允許的范圍內(nèi)，本活動一切解釋權(quán)歸藥智人才 下期活動預(yù)告 活動日期：5月20-5月24日 賞金金額：更多賺取賞金細(xì)則5月20日揭曉噢~   [更多]

1.Nakashima M, Morita J, Aizawa K. Pharamacokinetics and safety of tebipenem pivoxil fine granules, an oral carbapenem antibiotic, in healthy male volunteers. Jpn J Chemother. 2009;57(S–1):90–94 2.Baba S, Yamanaka N, Suzuki K, et al. Clinical efficacy, safety and PK-PD analysis of tebipenem pivoxil in a phase II clinical trial in otolaryngological infections. Jpn J Antibiot. 2009;62:155–177 3.Sunakawa K. Pharmacological properties and clinical performance of the novel oral carbapenem antimicrobial drug, “Tebipenem pivoxil” (Orapenem fine granules 10% for pediatric use). Jpn J Chemother. 2009;57:279–294 4.Yamanaka N, Furukawa M, Furuya, et al. Clinical efficacy of tebipenem pivoxil (ME1211), a novel oral carbapenem, in otolaryngological infections, a Phase II clinical trial (1). 45th Intersci Conf Antimicrob Agents Chemother (ICAAC) 2005; Abstract L-577 5.Iwata S, Ouchi K, Iwata N, et al. An open clinical study of tebipenem pivoxil in children with bacterial pneumonia. Jpn J Chemother. 2009;57(S–1):137–150   [更多]